Clearbridge Health, the medtech investor formerly known as Clearbridge Accelerator, is poised for an initial public offering (IPO) on the Catalist board of the Singapore Exchange.
Here are the key highlights of the IPO:
- Clearbridge Health's get a majority of its revenue from the provision of lab-testing services at its in-house laboratory, Sam Lab.
- In the six months to June 30, Clearbridge Health's net loss widened to S$2.03 million from S$1.27 million in the same period a year earlier.
- The company did not diclose the size of the IPO but said that it expects operating expenses to increase in the near term after the IPO.
- IPO proceeds will be used to expand Clearbridge's medical clinics and laboratory testing services business organically or through investments, acquisitions and joint ventures.
- Founded by non-executive non-independent chairman Johnson Chen in 2010, Clearbridge describes itself as a healthcare company with a focus on precision medicine in Asia, including laboratory testing, diagnostics and personalised treatments.
